MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

MDT

84.06

+0.04%↑

VEEV

226.15

-0.01%↓

A

105.7

-0.57%↓

WBA

11

+0.09%↑

CHE

551.68

-1.39%↓

Search

Ironwood Pharmaceuticals Inc

Abrir

SetorSaúde

0.87 3.57

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.8

Máximo

0.89

Indicadores-chave

By Trading Economics

Rendimento

-1.4M

2.3M

Vendas

-1M

91M

P/E

Médio do Setor

70.49

57.333

EPS

0.02

Margem de lucro

2.492

Funcionários

253

EBITDA

6.1M

33M

Dividendos

By Dow Jones

Próximos Ganhos

8 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-249M

118M

Abertura anterior

-2.7

Fecho anterior

0.87

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Ironwood Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

14 de abr. de 2025, 14:26 UTC

Grandes Movimentos do Mercado

Ironwood Pharma Shares Fall on Word of Confirmatory Phase 3 Apraglutide Trial

Comparação entre Pares

Variação de preço

Ironwood Pharmaceuticals Inc Previsão

Consenso de Avaliação

By TipRanks

Neutro

6 ratings

0

Comprar

6

Manter

0

Vender

Pontuação Técnica

By Trading Central

0.7222 / 0.9055Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Weak Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.